Overview

• All ten patients aged 1 to 24 experienced measurable hearing restoration following AAV-OTOF treatment.
• Average sound thresholds improved from 106 decibels to 52 decibels by six months after therapy.
• Most participants recovered some hearing within one month of receiving the inner-ear injection.
• No serious adverse events were reported during six- to twelve-month safety monitoring.
• Researchers will pursue five- to ten-year follow-up and adapt the AAV platform to other deafness genes such as GJB2 and TMC1.